Lori J. Pierce
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
520
Citations
32,470
Est. group size
~35
Recurring co-author estimate
Active years
57
Publishing since 1969
Typically publishes in teams of ~12 · 5% small-team papers (≤3 authors) · across 27 venues
- Targeting monopolar spindle kinase I (Mps1 or TTK) induces radiosensitization in syngeneic models of triple negative breast cancer (TNBC) and potentiates type I interferon (T1IFN) signaling
Neoplasia · 2025
- Abstract 1829: Potentiating antitumoral type 1 interferon immune signaling in triple-negative breast cancer (TNBC) via combination treatment of Aurora kinase B (AURKB) inhibition and radiation therapy
Cancer Research · 2025
- Response to Li, Liu, Duan, et al.
JNCI Journal of the National Cancer Institute · 2025
- Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
UNC Libraries · 2025
- Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment
UNC Libraries · 2025
- Augmenting Type 1 interferon antitumoral immune signaling in triple-negative breast cancer (TNBC) via combined radiotherapy and monopolar spindle kinase I (Mps1) inhibition 3799
The Journal of Immunology · 2025
- Supplementary Figure S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Supplementary Figure S5 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Supplementary Figure S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Supplementary Figure S3 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Supplementary Tables S5-S11 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Supplementary Figure S2 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Study protocol S1 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
2025
- Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis
JNCI Journal of the National Cancer Institute · 2024
- International Journal of Radiation Oncology*Biology*Physics×46
- Cancer Research×27
- Journal of Clinical Oncology×23
- Practical Radiation Oncology×12
- Journal of the National Comprehensive Cancer Network×8
- Corey Speers
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Tasha M. Hughes
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Arya Mariam Roy
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Kai Johnson
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sunil Badve
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile